Anthem Biosciences share price Live: Stock makes a strong debut, opens with 27% premium at ₹723.05 apiece on NSE

Anthem Biosciences share price made a strong debut on the bourses today. On NSE, Anthem Biosciences share price opened at ₹723.05 per share, 26.85% higher than the issue price of ₹570. On BSE, Anthem Biosciences share price today opened at ₹723.10 apiece, up 26.86% than the issue price.

Shares of Anthem Biosciences Ltd made its debut in the Indian stock market today. Anthem Biosciences IPO listing was scheduled at 10:00 IST on the bourses today (Monday, July 21). Anthem Biosciences shares was a part of Special Pre-open Session (SPOS), as per BSE notice. Experts predicted that the Anthem Biosciences IPO expected listing price is likely to see solid gains compared to its issue price. Anthem Biosciences IPO allotment status was finalised on Thursday, July 17.

Anthem Biosciences IPO opened for subscription on Monday, July 14 and closed on Wednesday, July 16. Anthem Biosciences IPO subscription status on the last bidding day was 63.86 times. The company fixed a price band of ₹540 to ₹570 per share for its IPO.

Anthem is a contract research, development, and manufacturing organization (CRDMO) that emphasizes innovation and technology, with comprehensive operations covering drug discovery, development, and manufacturing.

(Stay tune for live updates)

As per the RHP, the company's listed peers are Syngene International Limited, Sai Life Sciences Limited, Cohance Lifesciences Limited, and Divi’s Laboratories Limited.

Harshal Dasani Business of INVasset PMS, explained that what set Anthem apart is the depth of its CRDMO capabilities—spanning fermentation-based APIs, ADCs, peptides, oligonucleotides, and RNA therapeutics. With India’s largest fermentation capacity at 182 kL and over 675 clients across 44 countries, Anthem has built a high-barrier, scale-driven business model.

In FY25, the company clocked revenues of ₹1,844 crore, growing at 30% YoY, with EBITDA margins of nearly 37% and ROCE of around 27%. With no fresh issue component, there is zero dilution and no pressure to deploy new capital. If Q2 earnings keep pace and listing trends match market buzz, Anthem Biosciences could well position itself as the poster child of India’s biotech resurgence.

Anthem Biosciences marches into its stock market debut with soaring momentum. Its ₹3,395 crore IPO, structured entirely as an Offer for Sale, closed with a phenomenal ~67× subscription—led by QIBs at nearly 193×, NIIs at 45×, and retail at around 6×. Over the weekend, grey market premiums rose further to ₹165–170, indicating a likely listing price of ₹735–740, or a listing gain of approximately 29%. This level of interest reflects extraordinary investor conviction and places Anthem in an elite bracket of biotech listings in India.

Among the participants in the anchor book are notable investors such as Abu Dhabi Investment Authority, Government Pension Fund Global, Eastspring Investments, Amundi Funds, PineBridge Global Funds, Societe Generale, HDFC Mutual Fund, ICICI Prudential Mutual Fund, Axis Mutual Fund, UTI Mutual Fund, Quant Mutual Fund, and Motilal Oswal Mutual Fund, as stated in a circular posted on BSE's website.

Anthem Biosciences secured ₹1,016 crore from anchor investors ahead of the public subscription for its initial share-sale.

According to the circular, the company has issued 1.78 crore equity shares to 60 different funds at ₹570 each, which is the maximum end of the price range. This brings the total size of the transaction to ₹1,016 crore.

JM Financial, Citigroup Global Markets India, JP Morgan India, and Nomura Financial Advisory and Securities (India) are the book-running lead managers for the issue.

According to Mahesh M. Ojha, AVP Research & Business Development, Hensex Securities Pvt. Ltd, Anthem Biosciences share price is expected to make a strong debut on the stock exchanges. Given the robust investor demand during the IPO particularly from institutional investors the shares suggest a potential listing in the range of ₹700 or higher, translating into a premium of around 20–25%.

Anthem Biosciences Ltd's initial public offering was oversubscribed by 63.86 times on the final day of bidding, thanks to strong participation from institutional investors. According to data from the NSE, the initial share sale attracted bids for 2,81,44,34,740 shares, while only 4,40,70,682 shares were available.

The portion designated for qualified institutional buyers (QIBs) saw an impressive subscription rate of 182.65 times. Meanwhile, the segment for non-institutional investors was subscribed 42.35 times, and retail individual investors (RIIs) experienced a subscription rate of 5.64 times.

Anthem Biosciences IPO is entirely an offer-for-sale (OFS), the company will not receive any funds from the issue, and the proceeds will go to the selling shareholders.

Anthem Biosciences IPO GMP today or Anthem Biosciences IPO grey market premium is +177. This indicates Anthem Biosciences' share price was trading at a premium of ₹177 in the grey market, according to investorgain.com.

Considering the upper end of the IPO price band and the current premium in the grey market, the estimated listing price of Anthem Biosciences share price was indicated at ₹747 apiece, which is 31.05% higher than the IPO price of ₹570.

According to the grey market trends observed over the last 21 sessions, today's IPO GMP shows an upward trend and is anticipated to have a robust listing. The minimum GMP recorded is ₹0.00, whereas the peak GMP reaches ₹177, as per the experts at investorgain.com.

'Grey market premium' indicates investors' readiness to pay more than the issue price.

Disclaimer: The views and recommendations made above are those of individual analysts or broking companies, and not of Mint. We advise investors to check with certified experts before making any investment decisions.

Catch all the Business News , Market News , Breaking News Events and Latest News Updates on Live Mint. Download The Mint News App to get Daily Market Updates.

Download the Mint app and read premium stories